KALA Valuation
KALA BIO Inc
$
3.640
- Overview
- Forecast
- Valuation
KALA Relative Valuation
KALA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KALA is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for KALA's competitors is 16.75, providing a benchmark for relative valuation. KALA BIO Inc Corp (KALA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
People Also Watch
META
Meta Platforms Inc
637.565
USD
-0.45%
TSLA
Tesla Inc
347.385
USD
+1.55%
AAPL
Apple Inc
206.850
USD
-0.92%
MSFT
Microsoft Corp
455.290
USD
-0.78%
AMZN
Amazon.com Inc
205.080
USD
-0.52%
AVGO
Broadcom Inc
229.330
USD
-0.56%
WMT
Walmart Inc
98.150
USD
+0.03%
NVDA
NVIDIA Corp
133.530
USD
-1.50%
ORCL
Oracle Corp
158.235
USD
-0.88%
XOM
Exxon Mobil Corp
106.090
USD
-0.36%
FAQ
Is KALA BIO Inc (KALA) currently overvalued or undervalued?
KALA BIO Inc (KALA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 8.16. The fair price of KALA BIO Inc (KALA) is between NaN to NaN according to relative valuation methord.
What is KALA BIO Inc (KALA) fair value?
How does KALA's valuation metrics compare to the industry average?
What is the current P/B ratio for KALA BIO Inc (KALA) as of May 20 2025?
What is the current FCF Yield for KALA BIO Inc (KALA) as of May 20 2025?
What is the current Forward P/E ratio for KALA BIO Inc (KALA) as of May 20 2025?